Search research articles
Contact Us
Filters
Showing results (31-40 of 57) with videos related to
Page
of 6
Sort By:
British Journal of Haematology
|
March 5, 2020
Maintenance therapy with ex vivo expanded lymphokine-activated killer cells and rituximab in patients with follicular lymphoma is safe and may delay disease progression
Ascensión López-Díaz de Cerio, Ricardo García-Muñoz, Esther Pena, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 30, 2019
The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma
Laura Moreno, Cristina Perez, Aintzane Zabaleta, et al.
European Journal of Haematology
|
June 10, 2010
Clinical significance of occult cerebrospinal fluid involvement assessed by flow cytometry in non-Hodgkin's lymphoma patients at high risk of central nervous system disease in the rituximab era
Juan-Manuel Sancho, Alberto Orfao, Sandra Quijano, et al.
Future Science OA
|
December 13, 2019
Battle of Thermopylae: 300 Spartans (natural killer cells plus obinutuzumab) versus the immortal warriors (chronic lymphocytic leukemia cells) of Xerxes' army
Ricardo García-Muñoz, María-Josefa Nájera, Jesús Feliu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 20, 2009
Identification of leptomeningeal disease in aggressive B-cell non-Hodgkin's lymphoma: improved sensitivity of flow cytometry
Sandra Quijano, Antonio López, Juan Manuel Sancho, et al.
The Lancet. Haematology
|
April 1, 2016
First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosa-associated lymphoid tissue lymphoma (MALT2008-01): a multicentre, single-arm, phase 2 trial
Antonio Salar, Eva Domingo-Domenech, Carlos Panizo, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
April 7, 2015
Evaluation of clinical and biological prognostic factors in relapsed or refractory diffuse large B-cell lymphoma patients after previous treatment with rituximab and chemotherapy: results of the PRO-R-IPI study
Carlos Panizo, Anny Jaramillo Rodríguez, Gonzalo Gutiérrez, et al.
Blood Cancer Journal
|
July 10, 2024
Immune dysfunction prior to and during vaccination in multiple myeloma: a case study based on COVID-19
Esperanza Martín-Sánchez, Luis-Esteban Tamariz-Amador, Camila Guerrero, et al.
Blood
|
July 12, 2013
HLA specificities are related to development and prognosis of diffuse large B-cell lymphoma
Miguel Alcoceba, Elena Sebastián, Luis Marín, et al.
Blood Cancer Journal
|
December 15, 2021
Immune biomarkers to predict SARS-CoV-2 vaccine effectiveness in patients with hematological malignancies
Luis-Esteban Tamariz-Amador, Anna Martina Battaglia, Catarina Maia, et al.
Page
of 6
Search research articles
Search
Showing results (31-40 of 57) with videos related to
Sort By:
Page
of 6
British Journal of Haematology
|
March 5, 2020
Maintenance therapy with ex vivo expanded lymphokine-activated killer cells and rituximab in patients with follicular lymphoma is safe and may delay disease progression
Ascensión López-Díaz de Cerio, Ricardo García-Muñoz, Esther Pena, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 30, 2019
The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma
Laura Moreno, Cristina Perez, Aintzane Zabaleta, et al.
European Journal of Haematology
|
June 10, 2010
Clinical significance of occult cerebrospinal fluid involvement assessed by flow cytometry in non-Hodgkin's lymphoma patients at high risk of central nervous system disease in the rituximab era
Juan-Manuel Sancho, Alberto Orfao, Sandra Quijano, et al.
Future Science OA
|
December 13, 2019
Battle of Thermopylae: 300 Spartans (natural killer cells plus obinutuzumab) versus the immortal warriors (chronic lymphocytic leukemia cells) of Xerxes' army
Ricardo García-Muñoz, María-Josefa Nájera, Jesús Feliu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 20, 2009
Identification of leptomeningeal disease in aggressive B-cell non-Hodgkin's lymphoma: improved sensitivity of flow cytometry
Sandra Quijano, Antonio López, Juan Manuel Sancho, et al.
The Lancet. Haematology
|
April 1, 2016
First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosa-associated lymphoid tissue lymphoma (MALT2008-01): a multicentre, single-arm, phase 2 trial
Antonio Salar, Eva Domingo-Domenech, Carlos Panizo, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
April 7, 2015
Evaluation of clinical and biological prognostic factors in relapsed or refractory diffuse large B-cell lymphoma patients after previous treatment with rituximab and chemotherapy: results of the PRO-R-IPI study
Carlos Panizo, Anny Jaramillo Rodríguez, Gonzalo Gutiérrez, et al.
Blood Cancer Journal
|
July 10, 2024
Immune dysfunction prior to and during vaccination in multiple myeloma: a case study based on COVID-19
Esperanza Martín-Sánchez, Luis-Esteban Tamariz-Amador, Camila Guerrero, et al.
Blood
|
July 12, 2013
HLA specificities are related to development and prognosis of diffuse large B-cell lymphoma
Miguel Alcoceba, Elena Sebastián, Luis Marín, et al.
Blood Cancer Journal
|
December 15, 2021
Immune biomarkers to predict SARS-CoV-2 vaccine effectiveness in patients with hematological malignancies
Luis-Esteban Tamariz-Amador, Anna Martina Battaglia, Catarina Maia, et al.
Page
of 6